Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model

Journal of Magnetic Resonance Imaging

Volumn 45, Issue 1, 2017, Pages 270-280

  Yang, Shuo Hui ^a   Lin, Jiang ^a   Lu, Fang ^b   Han, Zhi Hong ^b   Fu, Cai Xia ^c   Lv, Peng ^a   Liu, Hao ^a   Gao, Dong Mei ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Siemens Mindit Magnetic Resonance Ltd Shenzhen   (China)

Author keywords

hepatocellular carcinoma; intravoxel incoherent motion; micro vessel density; necrosis; sorafenib

Indexed keywords

SORAFENIB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CAPILLARY DENSITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; HISTOLOGY; INTRAVOXEL INCOHERENT MOTION DIFFUSION WEIGHTED IMAGING; LIVER CELL CARCINOMA; MALE; MOUSE; NECROTIC FRACTION; NONHUMAN; PERFUSION FRACTION; PHYSICAL PARAMETERS; PRIORITY JOURNAL; PSEUDODIFFUSION COEFFICIENT; SEQUENTIAL HISTOLOGY; TREATMENT DURATION; TRUE DIFFUSION COEFFICIENT; TUMOR NECROSIS; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DRUG EFFECTS; IMAGE ENHANCEMENT; LIVER TUMOR; MAGNETIC RESONANCE ANGIOGRAPHY; MOTION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DIFFUSION MAGNETIC RESONANCE IMAGING; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MICE; MICE, INBRED BALB C; MOTION; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84995564754     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.25344     Document Type: Article

References (38)

1. Pircher A, Medinger M, Drevs J. Liver cancer: Targeted future options. World J Hepatol 2011;3:38–44.
2. Sampat KR, O'Neil B. Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist 2013;18:430–438.
3. Joo I, Lee JM, Grimm R, Han JK, Choi BI. Monitoring vascular disrupting therapy in a rabbit liver tumor model: relationship between tumor perfusion parameters at IVIM diffusion-weighted MR imaging and those at dynamic contrast-enhanced MR imaging. Radiology 2016;278:104–113.
4. Lewin M, Fartoux L, Vignaud A, Arrive L, Menu Y, Rosmorduc O. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol 2011;21:281–290.
5. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168:497–505.
6. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986;161:401–407.
7. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011;196:1351–1361.
8. Granata V, Fusco R, Catalano O, et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs: the role of intravoxel incoherent motion in diffusion-weighted imaging. PLoS One 2015;10:e0142876.
9. Joo I, Lee JM, Han JK, Choi BI. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology 2014;272:417–426.
10. Shirota N, Saito K, Sugimoto K, Takara K, Moriyasu F, Tokuuye K. Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. Cancer Imaging 2016;16:1.
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
12. Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015;7:1041–1053.
13. Llovet JM, Ducreux M, Lencioni R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–943.
14. Tian J, Tang ZY, Ye SL, et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer 1999;81:814–821.
15. Sun FX, Tang ZY, Lui KD, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer 1996;66:239–243.
16. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851–11858.
17. Yoon JH, Lee JM, Yu MH, Kiefer B, Han JK, Choi BI. Evaluation of hepatic focal lesions using diffusion-weighted MR imaging: comparison of apparent diffusion coefficient and intravoxel incoherent motion-derived parameters. J Magn Reson Imaging 2014;39:276–285.
18. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging—pilot study. Radiology 2008;249:891–899.
19. Geng W, Ng KT, Sun CK, et al. The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma. PLoS One 2011;6:e27362.
20. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875–1887.
21. Fujima N, Yoshida D, Sakashita T, et al. Intravoxel incoherent motion diffusion-weighted imaging in head and neck squamous cell carcinoma: assessment of perfusion-related parameters compared to dynamic contrast-enhanced MRI. Magn Reson Imaging 2014;32:1206–1213.
22. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011;4:40–44.
23. Schraml C, Kaufmann S, Rempp H, et al. Imaging of HCC—current state of the art. Diagnostics (Basel) 2015;5:513–545.
24. Guiu B, Petit JM, Capitan V, et al. Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study. Radiology 2012;265:96–103.
25. Chiaradia M, Baranes L, Van Nhieu JT, et al. Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis? J Magn Reson Imaging 2014;39:317–325.
26. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62.
27. Zwick S, Strecker R, Kiselev V, et al. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 2009;29:1125–1133.
28. Ferretti S, Allegrini PR, O'Reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:7773–7784.
29. Kakite S, Dyvorne H, Besa C, et al. Hepatocellular carcinoma: short-term reproducibility of apparent diffusion coefficient and intravoxel incoherent motion parameters at 3.0T. J Magn Reson Imaging 2015;41:149–156.
30. Guo Z, Zhang Q, Li X, Jing Z. Intravoxel incoherent motion diffusion weighted MR imaging for monitoring the instantly therapeutic efficacy of radiofrequency ablation in rabbit VX2 tumors without evident links between conventional perfusion weighted images. PLoS One 2015;10:e0127964.
31. Dyvorne H, Jajamovich G, Kakite S, Kuehn B, Taouli B. Intravoxel incoherent motion diffusion imaging of the liver: optimal b-value subsampling and impact on parameter precision and reproducibility. Eur J Radiol 2014;83:2109–2113.
32. Wetscherek A, Stieltjes B, Laun FB. Flow-compensated intravoxel incoherent motion diffusion imaging. Magn Reson Med 2015;74:410–419.
33. Fujita N, Harada K, Sakurai K, Akai Y, Kozuka T. Separation of diffusion and slow flow effects by use of flow rephasing and dephasing. Magn Reson Med 1992;24:109–122.
34. Klau M, Mayer P, Bergmann F, et al. Correlation of histological vessel characteristics and diffusion-weighted imaging intravoxel incoherent motion-derived parameters in pancreatic ductal adenocarcinomas and pancreatic neuroendocrine tumors. Invest Radiol 2015;50:792–797.
35. Lee HJ, Rha SY, Chung YE, et al. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. Magn Reson Med 2014;71:1554–1558.
36. Wu H, Liu H, Liang C, et al. Diffusion-weighted multiparametric MRI for monitoring longitudinal changes of parameters in rabbit VX2 liver tumors. J Magn Reson Imaging 2016 [Epub ahead of print] doi: 10.1002/jmri.25179.
37. Wu H, Hu M, Liu Z, et al. Intravoxel incoherent motion diffusion-weighted MRI for characterizing regional variability and monitoring serial changes of parameters in rabbit VX2 liver tumors. J Magn Reson Imaging 2016;43:173–180.
38. Ackerman JJ, Neil JJ. The use of MR-detectable reporter molecules and ions to evaluate diffusion in normal and ischemic brain. NMR Biomed 2010;23:725–733.